Stemrx Biosciences Unveils Micro Dose Infusion Therapy for Diabetes

This therapy administers insulin as a hormone rather than a drug, addressing core issues of diabetes and metabolic failure. 

Mumbai-based Stemrx Biosciences introduced a new Micro-Dose Infusion Therapy to treat diabetes and related metabolic disorders. 

This therapy administers insulin as a hormone rather than a drug, addressing the core issues of diabetes and metabolic failure. 

By replicating normal physiological processes, the Micro Dose System (MDS) reduces insulin resistance, enhances blood sugar absorption into cells, and converts it into energy.

Pradeep Mahajan, a regenerative medicine specialist at Stemrx Biosciences, announced plans to travel to Houston, Texas, for a medical training session. This visit is intended to facilitate the introduction of this therapy in Mumbai, India. 

"Micro Dose Infusion Therapy represents a significant advancement in the treatment of diabetes and its related disorders. By addressing the root cause of metabolic failure, we are not just managing symptoms but potentially reversing the disease's progression," Mahajan stated.

The therapy aims to mimic natural physiological processes, reducing insulin resistance and improving blood sugar absorption and conversion into energy. It is also effective in managing diabetes-related disorders like cardiovascular disease, neuropathy, nephropathy, retinopathy, and peripheral artery disease.

Addressing Diabetes at the Root

Pancreatic β-cells are crucial in maintaining glucose homeostasis by secreting insulin, the only hormone capable of lowering blood glucose levels. Impaired insulin secretion leads to chronic hyperglycemia, a hallmark of Type 2 diabetes (T2DM), affecting over 450 million people globally. 

The oscillatory release of insulin and glucose is essential for metabolic balance. In diabetes patients, malfunctioning pancreatic β-cells result in hepatic insulin resistance and the progression of type 2 diabetes.

Mahajan elaborated, "The goal of this technology is to mimic the body's natural insulin response, thereby improving overall health and quality of life for patients. Our upcoming training in Houston is a crucial step in bringing this treatment to patients in Mumbai."

Common medications and lifestyle changes often fail to address the long-term complications of diabetes, as they do not restore the natural periodic cycle of insulin in healthy physiology. 

Reportedly, the MDS has shown promising results in improving bodily functions and halting the progression of chronic diabetes-related diseases. The therapy achieves the oscillatory burst release of insulin through a medical device that delivers insulin in a pattern mimicking the body's natural response.

By introducing Micro Dose Infusion Therapy to India, Stemrx Biosciences aims to offer patients an alternative that targets the root cause of diabetes, providing hope for better health and improved quality of life.